Drug repurposing from an academic perspective

Drug Discovery Today: Therapeutic Strategies

Volumn 8, Issue 3-4, 2011, Pages 61-69

  Oprea, Tudor I ^a,b,c   Bauman, Julie E ^a   Bologa, Cristian G ^a   Buranda, Tione ^a,b   Chigaev, Alexandre ^a,b   Edwards, Bruce S ^a,b   Jarvik, Jonathan W ^d   Gresham, Hattie D ^a   Haynes, Mark K ^a   Hjelle, Brian ^a   Hromas, Robert ^e   Hudson, Laurie ^f   MacKenzie, Debra A ^f   Muller, Carolyn Y ^a,b   Reed, John C ^g   Simons, Peter C ^a   Smagley, Yelena ^a   Strouse, Juan ^a   Surviladze, Zurab ^a   Thompson, Todd ^f   Ursu, Oleg ^a   Waller, Anna ^a   Wandinger Ness, Angela ^a,b   Winter, Stuart S ^a,b   Wu, Yang ^a   Young, Susan M ^a   Larson, Richard S ^b   Willman, Cheryl ^b   Sklar, Larry A ^a,b   more..

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d CARNEGIE MELLON UNIVERSITY   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARKINSON AGENT; ASTEMIZOLE; BENZBROMARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CISPLATIN; CYCLOBENZAPRINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GUANOSINE TRIPHOSPHATASE; INTEGRIN; KETOROLAC; KETOROLAC TROMETAMOL; METHYLERGOMETRINE MALEATE; METNASE; MOMETASONE FUROATE; MULTIDRUG RESISTANCE PROTEIN 1; NAPROXEN; NEUROLEPTIC AGENT; PHENOTHIAZINE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PRODRUG; PROTEIN BCL 2; RALTEGRAVIR; SEDATIVE AGENT; TOLFENAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4; ZOSUQUIDAR;

ALZHEIMER DISEASE; ANALGESIA; ANTIBACTERIAL ACTIVITY; ARTICLE; AUTOPHAGY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER INHIBITION; CANCER PAIN; CARDIOTOXICITY; CELL DEATH; CLINICAL STUDY; CYTOREDUCTIVE SURGERY; DRUG APPROVAL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECALL; DRUG REPURPOSING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; FLOW CYTOMETRY; GOUT; HAY FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HIGH THROUGHPUT SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; INFECTION; LEUKOCYTE; LIGAND BINDING; LIVER TOXICITY; MEDICAL INFORMATICS; MUSCLE SPASM; OVARY CANCER; PARKINSON DISEASE; POSTPARTUM HEMORRHAGE; PROSTATE CANCER; QUORUM SENSING; RISK BENEFIT ANALYSIS; SEROTONIN SYNDROME; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; TOXICOLOGY; TRANSLATIONAL RESEARCH; UTERINE ATONY; VALIDATION PROCESS; VIRUS REPLICATION;

EID: 84862233340     PISSN: None     EISSN: 17406773     Source Type: Journal    
DOI: 10.1016/j.ddstr.2011.10.002     Document Type: Review

References (56)

1. O'Connor, K.A. and Roth, B.L. (2005) Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat. Rev. Drug Discov. 4, 1005-1014
2. Collins, F.S. (2010) Opportunities for research and NIH. Science 327, 36-37
3. Zerhouni, E.A. (2005) Translational and clinical science -time for a new vision. N. Engl. J. Med. 353, 1621-1623 (Pubitemid 41434645)
4. Austin, C.P. et al. (2004) NIH Molecular Libraries Initiative. Science 306, 1138-1139 (Pubitemid 39488980)
5. Hunter, A.J. (2008) The InnovativeMedicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov. Today 13, 371-373
6. Mossinghoff, G.J. (1999) Overview of the Hatch-Waxman Act and its impact on the drug development process. Food Drug Law J. 54, 187-194 (Pubitemid 29328042)
7. Ashburn, T.T. and Thor, K.B. (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673-683 (Pubitemid 39173508)
8. Chong, C.R. and Sullivan, D.J. (2006) New uses for old drugs. Nature 448, 645-646 (Pubitemid 47236844)
9. Huang, R. et al. (2011) The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med. 3 80ps16
10. Marusina, K. et al. The CTSA pharmaceutical assets portal -a public-private partnership model for drug repositioning. Drug Discov. Today: Ther. Strategies 8, 77-83
11. Mullard, A. (2011) Could pharma open its drug freezers? Nat. Rev. Drug Discov. 10, 399-400
12. Collins, F.S. (2011) Mining for therapeutic gold. Nat. Rev. Drug Discov. 10, 397
13. Dolgin, E. (2011) Nonprofit disease groups earmark grants for drug repositioning. Nat. Med. 17, 1027
14. Edwards, B.S. et al. (2004) Flow cytometry for high throughput, high content screening. Curr. Opin. Chem. Biol. 8, 392-398 (Pubitemid 38993732)
15. Fara, D.C. et al. (2006) Integration of virtual and physical screening. Drug Discov. Today Technol. 3, 377-385 (Pubitemid 46158388)
16. Oprea, T.I. et al. (2011) Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol. Inf. 30, 100-111
17. Sklar, L.A. and Edwards, B.S. (2010) HTS flow cytometry, small molecule discovery, and the NIH Molecular Libraries Initiative. In Flow Cytometry in Drug Discovery and Development (Litvin, V. and Marder, P., eds), pp. 71-98, John Wiley & Sons
18. Sklar, L.A. and Edwards, B.S. (2010) High thoughput flow cytometry for discovery at UNMCMD and the NIH Molecular Libraries Initiative. Drug Discov. World 13, 35-46
19. Dueñas-González, A. et al. (2008) The prince and the pauper. A tale of anticancer targeted agents. Mol. Cancer 7, 82
20. Bundscherer, A. and Hafner, C. (2010) Breathing new life into old drugs: Indication discovery by systems directed therapy. In From Molecular to Modular Tumor Therapy (Reichle, A., ed.), pp. 483-503, Springer Science+Business Media B.V.
21. Dudley, J.T. et al. (2011) Exploiting drug-disease relationships for computational drug repositioning. Brief. Bioinformatics 12, 303-311
22. Moriaud, F. et al. (2011) Identify drug repurposing candidates by mining the Protein Data Bank. Brief. Bioinformatics 12, 336-340
23. Gottlieb, A. et al. (2011) PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol. 7, 496
24. Lee, S.H. et al. (2005) The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc. Natl. Acad. Sci. U.S.A. 102, 18075-18080
25. Allen, C. et al. (2011) More forks on the road to replication stress recovery. J. Mol. Cell Biol. 3, 4-12
26. Oprea, T.I. and Matter, H. (2004) Integrating virtual screening in lead discovery. Curr. Opin. Chem. Biol. 8, 349-358 (Pubitemid 38996798)
27. Day, L.T. and Jeanmonod, R.K. (2008) Serotonin syndrome in a patient taking Lexapro and Flexeril: a case report. Am. J. Emerg. Med. 26, e1-e3
28. Gillman, P.K. (2009) Is there sufficient evidence to suggest cyclobenzaprine might be implicated in causing serotonin toxicity? Am. J. Emerg. Med. 27, 509-510
29. Mestres, J. et al. (2011) Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with the serotonin syndrome. Clin. Pharmacol. Ther. 90, 662-665
30. Lee, M.H.H. et al. (2008) A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Safety 31, 643-665
31. Gresham, H. et al. (2008) A Small Molecule that Targets a Signaling Pathway in AIP-Dependent Bacterial Quorum Sensing of S. aureus Agr3 agr Locus Genotype. NIH Chemical Probe report, http://www.mli.nih.gov/mli/?dl-id=701
32. Novick, R.P. and Geisinger, E. (2008) Quorum sensing in Staphylococci. Annu. Rev. Genet. 42, 541-564
33. Winter, S.S. et al. (2008) High throughput screening for daunorubicinmediated drug resistance identifies mometasone furoate as a novel ABCB1 reversal agent. J. Biomol. Screen. 13, 185-193 (Pubitemid 351322870)
34. Ivnitski-Steele, I. et al. (2008) High throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1 and ABCG2 transporters. Assay Drug Dev. Technol. 6, 263-276 (Pubitemid 351670375)
35. Cripe, L.D. et al. (2010) Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled, trial of the Eastern Cooperative Oncology Group (ECOG 3999). Blood 116, 4077-4085
36. Libby, E. and Hromas, R. (2010) Dismounting the MDR horse. Blood 116, 4037-4038
37. Simons, F.E. et al. (1988) Astemizole-induced torsade de pointes. Lancet 332, 624
38. Haynes, M.K. et al. (2009) Detection of intracellular granularity induction in prostate cancer cell lines by small molecules using the HyperCyt high throughput flow cytometry system. J. Biomol. Screen. 14, 596-609
39. Surviladze, Z. et al. (2012) High throughput flow cytometry bead-based multiplex assay for identification of Rho GTPase inhibitors. In Methods in Molecular Biology, vol. 827, Rho GTPases: Methods and Protocols (Rivero, Francisco, ed.), Humana Press ISBN 978-1-61779-441-4, in press
40. Pedersen, S.B. (1994) Biopharmaceutical aspects of tolfenamic acid. Pharmacol. Toxicol. 75 (Suppl. 2), 22-32 (Pubitemid 24288308)
41. Schroer, J. and Shenk, T. (2008) Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus. Proc. Natl. Acad. Sci. U.S.A. 105, 19468-19473
42. Coyne, C.B. and Bergelson, J.M. (2006) Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124, 119-131 (Pubitemid 43069314)
43. Estébanez-Perpiñá, E. et al. (2007) A surface on the androgen receptor that allosterically regulates coactivator binding. Proc. Natl. Acad. Sci. U.S.A. 104, 16074-16079 (Pubitemid 350099366)
44. Joh, T. et al. (2003) The protective effect of rebamipide on paracellular permeability of rat gastric epithelial cells. Alimentary Pharmacol. Ther. 18, 133-138 (Pubitemid 36898010)
45. DeSimone, R.W. et al. (2004) Privileged structures: applications in drug discovery. Comb. Chem. High Throughput Screen. 7, 473-493
46. Ohlow, M.J. and Moosmann, B. (2011) Phenothiazine: the seven lives of pharmacology's first lead structure. Drug Discov. Today 16, 119-131
47. Chigaev, A. et al. (2011) Discovery of very late antigen-4 (VLA-4, a4b1 integrin) allosteric antagonists. J. Biol. Chem. 286, 5455-5463
48. Chigaev, A. et al. (2009) Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation. J. Biol. Chem. 284, 14337-14346
49. Njus, B.H. et al. (2009) Conformational mAb as a tool for integrin ligand discovery. Assay Drug Dev. Technol. 7, 507-515
50. Reed, J.C. (1997) Double identity for proteins of the Bcl-2 family. Nature 387, 773-776 (Pubitemid 27270895)
51. Zhai, D. et al. (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ. 13, 1419-1421 (Pubitemid 44057478)
52. Simons, P. et al. (2011) Simultaneous in vitro molecular screening of protein-peptide interactions by flow cytometry using six Bcl-2 family proteins as examples. Nat. Protoc. 6, 243-253
53. Curpan, R.F. et al. (2011) High-throughput screen for the chemical inhibitors of antiapoptotic Bcl-2 family proteins by multiplex flow cytometry. Assay Drug Dev. Technol. 6, 943-952
54. Kitada, S. et al. (2008) M. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 111, 3211-3219
55. Szent-Gyorgyi, C. et al. (2008) Fluorogen-activating single-chain antibodies for imaging cell surface proteins. Nat. Biotechnol. 26, 235-240 (Pubitemid 351225952)
56. Fisher, G.W. et al. (2010) Detection and quantification of b2AR internalization in living cells using FAP-based biosensor technology. J. Biomol. Screen. 15, 703-709